BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CLN-978 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CLN-978\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06613360-5844@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:CLN-978: Phase 1 readout est. (NCT06613360)
DESCRIPTION:CLN-978\, phase 1\, Systemic Lupus Erythematosus.\nStudy: A Stu
 dy of CLN-978\, a Subcutaneously Administered CD19-directed T Cell Engager
 \, in Subjects With Systemic Lupus Erythematosus\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cln-978#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06613360
URL:https://assetmemo.bio/drug/cln-978#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994143-5844@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:CLN-978: Phase 1 readout est. (NCT06994143)
DESCRIPTION:CLN-978\, phase 1\, Rheumatoid Arthritis.\nStudy: A Study of CL
 N-978\, a Subcutaneously Administered CD19-directed T Cell Engager\, in Su
 bjects With Rheumatoid Arthritis\nEstimated primary completion: 30 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cln-978#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06994143
URL:https://assetmemo.bio/drug/cln-978#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07041099-5844@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:CLN-978: Phase 1 readout est. (NCT07041099)
DESCRIPTION:CLN-978\, phase 1.\nStudy: A Study of CLN-978\, a Subcutaneousl
 y Administered CD19-directed T Cell Engager\, in Subjects With Sjogren's D
 isease\nEstimated primary completion: 15 March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cln-978#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07041099
URL:https://assetmemo.bio/drug/cln-978#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
